Pirfenidone inhibits macrophage infiltration in 5/6 nephrectomized rats

American Journal of Physiology - Renal Physiology

Volumn 304, Issue 6, 2013, Pages

  Chen, Jun Feng ^a   Ni, Hai Feng ^a   Pan, Ming Ming ^a   Liu, Hong ^a   Xu, Min ^a   Zhang, Ming Hui ^a   Liu, Bi Cheng ^a  

^a MEDICAL SCHOOL OF SOUTHEAST UNIVERSITY   (China)

Author keywords

Inflammation; Macrophage; Pirfenidone; Renal fibrosis

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; ARGINASE 1; BETA N ACETYLHEXOSAMINIDASE; C REACTIVE PROTEIN; CALVASCULIN; CD163 ANTIGEN; CD86 ANTIGEN; CHEMOKINE RECEPTOR CCR7; CHLORDANE; CONNECTIVE TISSUE GROWTH FACTOR; DECTIN 1; FIBRONECTIN; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 6; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MONOCYTE CHEMOTACTIC PROTEIN 1; PIRFENIDONE; TRANSFORMING GROWTH FACTOR BETA1; TUMOR NECROSIS FACTOR ALPHA; ACETYLGLUCOSAMINIDASE; BIOLOGICAL MARKER; CCL2 PROTEIN, RAT; NONSTEROID ANTIINFLAMMATORY AGENT; PYRIDONE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL INFILTRATION; CONTROLLED STUDY; FIBROSING ALVEOLITIS; KIDNEY FIBROSIS; MACROPHAGE; MALE; NEPHRECTOMY; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN URINE LEVEL; PROTEINURIA; RAT; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SYSTOLIC BLOOD PRESSURE; WESTERN BLOTTING; ANIMAL; BLOOD PRESSURE; CHRONIC KIDNEY FAILURE; DRUG EFFECT; DRUG SCREENING; ENZYMOLOGY; IMMUNOLOGY; KIDNEY; METABOLISM; NEPHROSCLEROSIS; PATHOLOGY; PHENOTYPE; SPRAGUE DAWLEY RAT;

ACETYLGLUCOSAMINIDASE; ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BIOLOGICAL MARKERS; BLOOD PRESSURE; CHEMOKINE CCL2; CHEMOKINE CCL3; DRUG EVALUATION, PRECLINICAL; KIDNEY; MACROPHAGES; MALE; NEPHRECTOMY; NEPHROSCLEROSIS; PHENOTYPE; PROTEINURIA; PYRIDONES; RATS; RATS, SPRAGUE-DAWLEY; RENAL INSUFFICIENCY, CHRONIC;

MLCS; MLOWN;

EID: 84877929064     PISSN: 1931857X     EISSN: 15221466     Source Type: Journal    
DOI: 10.1152/ajprenal.00507.2012     Document Type: Article

References (42)

1. Anders HJ, Ryu M. Renal microenvironments and macrophage pheno-types determine progression or resolution of renal inflammation and fibrosis. Kidney Int 80: 915-925, 2011.
2. Armendáriz-Borunda J, Islas-Carbajal MC, Meza-García E, Rincón AR, Lucano S, Sandoval AS, Salazar A, Berumen J, Alvarez A, Covarrubias A, Aréchiga G, García L. A pilot study in patients with established advanced liver fibrosis using pirfenidone. Gut 55: 1663-1665, 2006.
3. Badylak SF, Valentin JE, Ravindra AK, McCabe GP, Stewart-Akers AM. Macrophage phenotype as a determinant of biologic scaffold remodeling. Tissue Eng 14: 1835-1842, 2008.
4. Cho ME, Smith DC, Branton MH, Penzak SR, Kopp JB. Pirfenidone slows renal function decline in patients with focal segmental glomerulo-sclerosis. Clin J Am Soc Nephrol 2: 906-913, 2007.
5. Daley JM, Brancato SK, Thomay AA, Reichner JS, Albina JE. The phenotype of murine wound macrophages. J Leukoc Biol 87: 59-67, 2010.
6. David S, Kroner A. Repertoire of microglial and macrophage responses after spinal cord injury. Nat Rev Neurosci 12: 388-399, 2011.
7. Goicoechea M, de Vinuesa SG, Verdalles U, Ruiz-Caro C, Ampuero J, Rincón A, Arroyo D, Luño J. Effect of allopurinol in chronic kidney disease progression and cardiovascular risk. Clin J Am Soc Nephrol 5: 1388-1393, 2010.
8. Han Y, Ma FY, Tesch GH. C-fms blockade reverses glomerular macro-phage infiltration and halts development of crescentic anti-GBM glomer-ulonephritis in the rat. Lab Invest 91: 978-991, 2011.
9. Henderson NC, Mackinnon AC, Farnworth SL, Atkinson KM, Wilkinson T, Dhaliwal K, Hayashi K, Simpson AJ, Rossi AG, Haslett C, Sethi T. Galectin-3 expression and secretion links macrophages to the promotion of renal fibrosis. Am J Pathol 172: 288-298, 2008.
10. Hesse M, Modolell M, La Flamme AC, Schito M, Fuentes JM, Cheever AW, Pearce EJ, Wynn TA. Differential regulation of nitric oxide synthase-2 and arginase-1 by type 1/type 2 cytokines in vivo: granulomatous pathology is shaped by the pattern of L-arginine metabolism. J Immunol 167: 6533-6544, 2001.
11. Hunter MG, Hurwitz S, Bellamy CO, Duffield JS. Quantitative mor-phometry of lupus nephritis: the significance of collagen, tubular space, and inflammatory infiltrate. Kidney Int 67: 94-102, 2005.
12. Iyer SN, Hyde DM, Girl SN. Anti-inflammatory effect of pirfenidone in the bleomycin-hamster model of lung inflammation. Inflammation 24: 477-491, 2000.
13. Iyer SN, Wild JS, Schiedt MJ, Hyde DM, Margolin SB, Giri SN. Dietary intake of pirfenidone ameliorates bleomycin-induced lung fibrosis in hamsters. J Lab Clin Med 125: 779-785, 1995.
14. Leh S, Vaagnes Ø, Margolin SB, Iversen BM, Forslund T. Pirfenidone and candesartan ameliorate morphological damage in mild chronic anti-GBM nephritis in rats. Nephrol Dial Transplant 20: 71-82, 2005.
15. Li Q, Liu BC, Lv LL, Ma KL, Zhang XL, Phillips AO. Monocytes induce proximal tubular epithelial-mesenchymal transition through NF-kappa B dependent upregulation of ICAM-1. J Cell Biochem 112: 1585- 1592, 2011.
16. Liu H, Drew P, Cheng Y, Visner GA. Pirfenidone inhibits inflammatory responses and ameliorates allograft injury in a rat lung transplant model. J Thorac Cardiovasc Surg 130: 852-858, 2005.
17. Lucas M, Stuart LM, Savill J, Lacy-Hulbert A. Apoptotic cells and innate immune stimuli combine to regulate macrophage cytokine secretion. J Immunol 171: 2610-2615, 2003.
18. Macías-Barragán J, Sandoval-Rodríguez A, Navarro-Partida J, Ar-mendáriz-Borunda J. The multifaceted role of pirfenidone and its novel targets. Fibrogenesis Tissue Repair 3: 1-11, 2010.
19. Mahdavian Delavary B, van der Veer WM, van Egmond M, Niessen FB, Beelen RH. Macrophages in skin injury and repair. Immunobiology 216: 753-762, 2011.
20. Mantovani A, Sica A, Sozzani S, Allavena P, Vecchi A, Locati M. The chemokine system in diverse forms of macrophage activation and polarization. Trends Immunol 25: 677-686, 2004.
21. Mantovani A, Sozzani S, Locati M, Allavena P, Sica A. Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol 23: 549-555, 2002.
22. Martinez FO, Sica A, Mantovani A, Locati M. Macrophage activation and polarization. Front Biosci 13: 453-461, 2008.
23. Mckane BW, Fernandez F, Narayanan K, Marshbank S, Margolin SB, Jendrisak M, Mohanakumar T. Pirfenidone inhibits obliterative airway disease in a murine heterotopic tracheal transplant model. Trans-platation 77: 664-669, 2004.
24. Meuwese CL, Stenvinkel P, Dekker FW, Carrero JJ. Monitoring of inflammation in patients on dialysis: forewarned is forearmed. Nat Rev Nephrol 7: 166-176, 2011.
25. Mosser DM. The many faces of macrophage activation. J Leukoc Biol 73: 209-212, 2003.
26. Ni J, Huang HQ, Lü LL, Zheng M, Liu BC. Influence of irbesartan on the urinary excretion of cytokines in patients with chronic kidney disease. Chin Med J (Engl) 125: 1147-1152, 2012.
27. Noble PW, Albera C, Bradford WZ, Bradford WZ, Costabel U, Glassberg MK, Kardatzke D, King TE Jr, Lancaster L, Sahn SA, Szwarcberg J, Valeyre D, du Bois RM; CAPACITY Study Group. Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials. Lancet 377: 1760-1769, 2011.
28. Oku H, Shimizu T, Kawabata T, Nagira M, Hikita I, Ueyama A, Matsushima S, Torii M, Arimura A. Antifibrotic action of pirfenidone and prednisolone: different effects on pulmonary cytokines and growth factors in bleomycin-induced murine pulmonary fibrosis. Eur J Pharmacol 590: 400-408, 2008.
29. Orme J, Mohan C. Macrophage subpopulations in systemic lupus ery-thematosus. Discov Med 13: 151-158, 2012.
30. RamachandraRao SP, Zhu Y, Ravasi T, McGowan TA, Toh I, Dunn SR, Okada S, Shaw MA, Sharma K. Pirfenidone is renoprotective in diabetic kidney disease. J Am Soc Nephrol 20: 1765-1775, 2009.
31. Rincon J, Romero M, Viera N, Pedreañez A, Mosquera J. Increased oxidative stress and apoptosis in acute puromycin aminonucleoside ne-phrosis. Int J Exp Pathol 85: 25-33, 2004.
32. Rubino CM, Bhavnani SM, Ambrose PG, Forrest A, Loutit JS. Effect of food and antacids on the pharmacokinetics of pirfenidone in older healthy adults. Pulm Pharmacol Ther 22: 279-285, 2009.
33. Ryu M, Kulkarni OP, Radomska E, Miosge N, Gross O, Anders HJ. Bacterial CpG-DNA accelerates Alport glomerulosclerosis by inducing an M1 macrophage phenotype and tumor necrosis factor-a-mediated podo-cyte loss. Kidney Int 79: 189-198, 2011.
34. Sharma K, Ix JH, Mathew AV, Cho M, Pflueger A, Dunn SR, Francos B, Sharma S, Falkner B, McGowan TA, Donohue M, Ramachandra-rao S, Xu R, Fervenza FC, Kopp JB. Pirfenidone for diabetic nephropathy. J Am Soc Nephrol 22: 1144-1151, 2011.
35. Shimizu T, Fukagawa M, Kuroda T, Hata S, Iwasaki Y, Nemoto M, Shirai K, Yamauchi S, Margolin SB, Shimizu F, Kurokawa K. Pirfenidone prevents collagen accumulation in the remnant kidney in rats with partial nephrectomy. Kidney Int Suppl 63: S239-243, 1997.
36. Takakuta K, Fujimori A, Chikanishi T, Tanokura A, Iwatsuki Y, Yamamoto M, Nakajima H, Okada M, Itoh H. Renoprotective properties of pirfenidone in subtotally nephrectomized rats. Eur J Pharmacol 629: 118-124, 2010.
37. Vernon MA, Mylonas KJ, Hughes J. Macrophages and renal fibrosis. Semi Nephrol 30: 302-317, 2010.
38. Vielhauer V, Kulkarni O, Reichel CA, Anders HJ. Targeting the recruitment of monocytes and macrophages in renal disease. Semin Neph-rol 30: 318-333, 2010.
39. Visner GA, Liu F, Bizargity P, Liu H, Liu K, Yang J, Wang L, Hancock WW. Pirfenidone inhibits T-cell activation, proliferation, cyto-kine and chemokine production, and host alloresponses. Transplantation 88: 330-338, 2009.
40. Walker JE, Giri SN, Margolin SB. A double-blind, randomized, controlled study of oral pirfenidone for treatment of secondary progressive multiple sclerosis. Mult Scler 11: 149-158, 2005.
41. Wu H, Walters G, Knight JF, Alexander SI. DNA vaccination against specific pathogenic TCRs reduces proteinuria in active Hey-mann nephritis by inducing specific autoantibodies. J Immunol 171: 4824-4829, 2003.
42. Wynn TA. Integrating mechanisms of pulmonary fibrosis. J Exp Med 208: 1339-1350, 2011.